6-amino-N-hydroxyhexanamide | 2214-89-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-amino-N-hydroxyhexanamide
• 英文别名: ε-Amino-caprohydroxamsaeure
• CAS: 2214-89-3
• 化学式: C₆H₁₄N₂O₂
• 分子量: 146.189
• InChiKey: HAQVDFULTKFINY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  N-ethoxycarbonylsuccinimide 、 6-amino-N-hydroxyhexanamide 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Eine enzymatische Umlagerung cancerogener Nitrosamine

  摘要：

  癌变性亚硝胺在肝脏和肾脏匀浆的作用下首先转化成相应的酰胺氧化物（II）。一种酶促反应引起酰胺氧化物的水解成为一级胺和羟肟酸（III），而在缓慢进行的自发水解中也会脱离羟胺。回收的亚硝胺和代谢产物的总和在定量处理中在误差范围内等于所使用的亚硝胺总量，表明其他可能导致癌变的代谢反应是不可能的。从不同效应物的影响可以推断出巯基酶的参与。

  DOI：

  10.1515/znb-1970-0315
• 作为产物：
  描述：

  己内酰胺 在 硫酸羟胺 作用下， 以 甲醇 为溶剂， 生成 6-amino-N-hydroxyhexanamide
  参考文献：
  名称：

  Zil'berman,E.N. et al., Journal of General Chemistry of the USSR, 1965, vol. 35, p. 861 - 863

  摘要：

  DOI：

文献信息

• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• HDAC Inhibitors
  申请人：Ashwell Mark A.

  公开号：US20100261710A1

  公开（公告）日：2010-10-14

  The present invention provides hydroxamic acid compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the hydroxamic acid compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.

  本发明提供了羟肟酸化合物以及这些化合物的制备方法。本发明还涉及包含羟肟酸化合物的药物组合物。本发明提供了治疗细胞增殖性疾病（如癌症）的方法，通过向需要治疗的受试者施用本发明化合物的治疗有效剂量。
• CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20100249197A1

  公开（公告）日：2010-09-30

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q 1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR 1 C(═O)— and —C(═O)NR 1 —; R 1 is an amido substituent; and, Q 2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psorias

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，其具有式（1），其中：A是芳基基团；Q1是至少具有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺连接：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；以及Q2是酸前导基团；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包括这种化合物的制药组合物，以及使用这种化合物和组合物，在体内外抑制HDAC，例如抑制增殖性疾病，如癌症和银屑病。
• Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
  申请人：TopoTarget UK Limited

  公开号：EP1598067A1

  公开（公告）日：2005-11-23

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR1C(=O)- and -C(=O)NR1-; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof, for use in the treatment of parasitic infections, such as malaria.

  本发明涉及某些抑制 HDAC 活性的活性氨基甲酸化合物，它们具有下式： 其中A是芳基；Q1是具有至少2个碳原子骨架的芳基领导基团；J是选自-NR1C(＝O)-和-C(＝O)NR1-的酰胺连接；R1是氨基取代基；Q2是酸领导基团；及其药学上可接受的盐、溶液剂、酰胺、酯、醚、化学保护形式和原药，用于治疗寄生虫感染，如疟疾。
• [EN] HDAC INHIBITORS<br/>[FR] INHIBITEURS DES HDAC
  申请人：ARQULE INC

  公开号：WO2009026446A9

  公开（公告）日：2010-03-11